Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;85(20):10826-33.
doi: 10.1128/JVI.00804-11. Epub 2011 Aug 17.

Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy

Mark H Kuniholm  1 , Xiaojiang Gao, Xiaonan Xue, Andrea Kovacs, Kathryn Anastos, Darlene Marti, Ruth M Greenblatt, Mardge H Cohen, Howard Minkoff, Stephen J Gange, Melissa Fazzari, Mary A Young, Howard D Strickler, Mary Carrington
Affiliations

Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy

Mark H Kuniholm et al. J Virol. 2011 Oct.

Abstract

While the human leukocyte antigen (HLA) genotype has been associated with the rate of HIV disease progression in untreated patients, little is known regarding these relationships in patients using highly active antiretroviral therapy (HAART). The limited data reported to date identified few HLA-HIV disease associations in patients using HAART and even occasional associations that were opposite of those found in untreated patients. We conducted high-resolution HLA class I and II genotyping in a random sample (n = 860) of HIV-seropositive women enrolled in a long-term cohort initiated in 1994. HLA-HIV disease associations before and after initiation of HAART were examined using multivariate analyses. In untreated HIV-seropositive patients, we observed many of the predicted associations, consistent with prior studies. For example, HLA-B*57 (β = -0.7; 95% confidence interval [CI] = -0.9 to -0.5; P = 5 × 10⁻¹¹) and Bw4 (β = -0.2; 95% CI = -0.4 to -0.1; P = 0.009) were inversely associated with baseline HIV viral load, and B*57 was associated with a low risk of rapid CD4+ decline (odds ratio [OR] = 0.2; 95% CI = 0.1 to 0.6; P = 0.002). Conversely, in treated patients, the odds of a virological response to HAART were lower for B*57:01 (OR = 0.2; 95% CI = 0.0 to 0.9; P = 0.03), and Bw4 (OR = 0.4; 95% CI = 0.1 to 1.0; P = 0.04) was associated with low odds of an immunological response. The associations of HLA genotype with HIV disease are different and sometimes even opposite in treated and untreated patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahdieh L., et al. 2000. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am. J. Epidemiol. 152:923–933 - PubMed
    1. Ahuja S. K., et al. 2008. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14:413–420 - PMC - PubMed
    1. Al-Harthi L., et al. 2006. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J. Infect. Dis. 193:1202–1210 - PMC - PubMed
    1. Anonymous 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommend. Rep. 41(RR-17): 1–19 - PubMed
    1. Barkan S. E., et al. 1998. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 9:117–125 - PubMed

Publication types